

Simbec and Sekino are proud to announce their strategic alliance for the conduct of bridging studies in healthy volunteers.

Simbec Research Ltd and the Japanese CRO Sekino Clinical Pharmacology Clinic have created a strategic alliance to perform bridging studies in Japanese and Caucasian volunteers. This unique offering will enable bridging studies to be performed simultaneously at Simbec Research Ltd and Sekino sites using a single protocol.

This creative alliance will provide high quality comparisons of data derived from Caucasian and Japanese subjects maintained within their own environment. Each population will consume a standard diet peculiar to their habitat and culture.

Simbec Research Limited is one of Europe's foremost CROs with over 30 years experience in clinical drug development specialising in healthy volunteer and patient volunteer studies (Phase I-IIa). Simbec's 48 bed Clinical Pharmacology Unit (CPU), has been optimised for the conduct and management of new chemical entity, First into Man, Phase I studies.

Sekino Clinical Pharmacology Clinic is one of Japan's premier Phase I clinics with a long history of conducting successful clinical pharmacology studies and with specialist expertise in CYP450 genotyping.

A dedicated Project Manager will be appointed at the beginning of the study to coordinate your programme and will direct the project accordingly to a single protocol to be used in the two centres.

Simbec's integrated and extensive Bioanalytical unit will provide a single site for analysis of drug levels in biological fluids and define the pharmacokinetic profiles.

Data management and report writing can be produced in either language.

For more information regarding this novel approach to bridging studies please contact:

Dr Peter Dewland
Medical Director
Simbec Research Ltd,
T: +44 (0) 1443 694302
E: peter.dewland@simbec.co.uk

Mr Kazuhiro Ishii
Head of Clinical Trial Division
Sekino Clinical Pharmacology Clinic
T: +81 3 5396 4530
E: ishii_kazuhiro@seri.co.jp